Peripheral Arterial Disease Clinical Trial
Official title:
Promoting Walking in African Americans With Peripheral Arterial Disease
The investigators are conducting a clinical research trial to determine the role of motivational interviewing (MI) on promoting home-based walking therapy to improve walking ability in African Americans with peripheral arterial disease (PAD). African Americans are more than two times as likely as non-Hispanic whites to suffer from PAD. For patients with PAD, there is a significant risk for poor walking ability and limb loss. One major treatment for PAD is walking therapy but the traditional methods for the delivery of this treatment have required frequent visits to a university or hospital-based site. The investigators will address the role of self-managed walking program, to be conducted at or near the home, to improve limb function. In order to motivate the participants to walk, the investigators included two different intervention strategies: MI and patient-centered counseling for exercise (PACE). The investigators hypothesize that participants randomized to the MI arm will have a greater increase in their walking distance, compared to those receiving Patient-Centered Assessment and Counseling for Exercise (PACE) and the control group.
Status | Completed |
Enrollment | 174 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. African American (determined by self-report) 2. Lived most of their life in the United States 3. Resting ABI <0.995 4. English Speaking 5. Has a telephone Exclusion Criteria: 1. Currently walking for exercise at least 5 days per week (i.e., a PACE score ranging from 5-8); the rationale is that a person who is currently walking for at least 5 days per week is already sufficiently active and therefore not a member of the target population for our motivational home-based walking intervention. 2. Prior major amputation (foot or lower leg) or critical leg ischemia (tissue loss, gangrene, or ulcers) 3. Rest pain with ABI <0.4 and non-palpable femoral pulses without prior evaluation by a vascular surgeon, given the need for evaluation for the role of more invasive therapy prior to recommending walking therapy 4. Leg revascularization within 3 months of enrollment or plans for revascularization during the study period; the rationale is that post intervention recovery and potential complications are likely to limit the patient's ability to adhere to the study protocol. 5. Use of supplemental oxygen; the rationale for this is concern for participant safety and potential limited ability to participate in the study secondary to breathing difficulty. 6. Myocardial infarction within the preceding 3 months; the rationale for this is participant safety and the potential risk for complications and/or the need for supervised cardiac rehabilitation following the event. 7. Resting blood pressure > 200/110 mmHg; the rationale for this is participant safety, as blood pressure may further increase during exercise and increase risk for a cerebrovascular event or myocardial infarction. 8. Exercise-induced coronary ischemic symptoms, or exercise-induced ST depression > 2.0 mm; the rationale for this is participant safety and the need for further cardiac evaluation prior to involvement in walking therapy (American College of Cardiology/American Heart Association, 2006). 9. Inability to walk for 2 minutes; the rationale being that people who cannot walk for 2 minutes would not be able to complete the necessary submaximal treadmill test, which is used to screen for coronary ischemic symptoms. We will also exclude anyone who can walk for 20 minutes or more during the submaximal treadmill test. Anyone who can complete the submaximal test would not have significant walking impairment and would not get that much out of the study. Short Physical Performance Battery score of 10 or higher as such persons do not have a clinically significant impairment in mobility; therefore, we will exclude anyone who scores a 10 or higher (out of a maximum of 12 points). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Clinical and Translational Science Unit | Fairway | Kansas |
United States | KU School of Medicine-Wichita | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
University of Kansas Medical Center | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 Minute Walk Test | Distance walked in 6 minutes | 6 months | No |
Secondary | Short Physical Performance Battery (SPPB) | Assessment of balance and basic physical mobility | Baseline | No |
Secondary | Blood work for glucose and lipid levels | glycosylated hemoglobin (HbA1C) and a fasting lipid profile | Baseline | No |
Secondary | Adherence to Physical Activity | The participants will be asked to wear accelerometers for seven days at each of the three time points. | Baseline | No |
Secondary | Ankle-Brachial Index (ABI) | An assessment that is used to determine the severity of peripheral arterial disease. | Baseline | No |
Secondary | Quality of Life | The SF-12 and VascQOL questionnaires will be used to assess QOL. | Baseline | No |
Secondary | 6 minute walk test | Distance walked in 6 minutes | 12 months | No |
Secondary | 6 minute walk test | Distance walked in 6 minutes | Baseline | No |
Secondary | Short physical performance battery (SPPB) | Assessment of balance and basic physical mobility | 6 months | No |
Secondary | Short Physical Performance Battery (SPPB) | Assessment of balance and basic physical mobility | 12 months | No |
Secondary | Blood work for glucose and lipid levels | HbA1C and a fasting lipid profile | 6 months | No |
Secondary | Blood work for glucose and lipid levels | HbA1C and a fasting lipid profile | 12 months | No |
Secondary | Ankle-Brachial Index (ABI) | An assessment that is used to determine the severity of peripheral arterial disease. | 12 months | No |
Secondary | Quality of Life | The SF-12 and VascQOL questionnaires will be used to assess QOL. | 6 months | No |
Secondary | Quality of life | The SF-12 and VascQOL questionnaires will be used to assess QOL. | 12 months | No |
Secondary | Dietary habits for fats and fruits and vegetables | Assessment of fats and fruit and vegetable intake | baseline | No |
Secondary | Dietary habits for fats and fruits and vegetables | Assessment of fats and fruit and vegetable intake | 6 months | No |
Secondary | Dietary habits for fats and fruits and vegetables | Assessment of fats and fruit and vegetable intake | 12 months | No |
Secondary | Adherence to Physical Activity | The participants will be asked to wear accelerometers for seven days at each of the three time points. | 6 months | No |
Secondary | Adherence to Physical Activity | The participants will be asked to wear accelerometers for seven days at each of the three time points. | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |